Prostaglandin Analogue–Containing Eyelash Serums and Their Potential Ocular Implications: A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.78.76474Keywords
prostaglandin analogues, cosmetic eyelash serums, eyelash hypotrichosis, adverse effects, cosmetovigilance, intraocular pressureAbstract
Background: The rising popularity of over-the-counter eyelash serums containing prostaglandin analogues (PGAs) has raised safety concerns due to their pharmacological origin as glaucoma treatments and their current cosmetic misuse without medical supervision.
Aim: To evaluate scientific evidence regarding the safety of PGA-containing eyelash serums, focusing on mechanisms, adverse effects, impact on intraocular pressure (IOP), and regulatory challenges.
Material and Methods: A comprehensive literature search was conducted across PubMed/MEDLINE, Scopus, and Web of Science for publications up to September 2026. Retrieved studies were qualitatively assessed and synthesized.
Results: Chronic exposure to cosmetic PGAs is associated with periocular hyperpigmentation, conjunctival hyperaemia, tear film instability, meibomian gland dysfunction, and prostaglandin-associated periorbitopathy (PAP). While direct links to de novo glaucoma are lacking, active compounds can alter IOP and affect diagnostic accuracy. Regulatory bodies like the SCCS highlight insufficient safety data for safe cosmetic use near the eye.
Conclusions: PGA-containing serums are pharmacologically active and not inert cosmetics, requiring stricter regulatory oversight, transparent labelling, enhanced cosmetovigilance, and clinical awareness.
References
1. Grand View Research. Eyelash serum market size, share & trends analysis report, 2024–2030 [Internet]. San Francisco (CA): Grand View Research; 2024 [cited 2026 Sep 28]. Available from: https://www.grandviewresearch.com/industry-analysis/eyelash-serum-market-report
2. Pandey A, Jatana GK, Sonthalia S. Cosmeceuticals. In: Personal Care Products and Human Health. 2023. p. 79–95. doi:10.1016/B978-0-323-99684-6.00007-0
3. Baiyasi M, St Claire K, Hengy M, Tur K, Fahs F, Potts G. Eyelash serums: a comprehensive review. J Cosmet Dermatol. 2024;23(7):2328–44. doi:10.1111/jocd.16278
4. Couteau C, Coiffard L. Prostaglandin analogues in cosmetic products formulated for eyelash lengthening. Ann Pharm Fr. 2026;84(5):889–98. doi:10.1016/j.pharma.2026.06.007
5. Hopley C, Corless S, Webster W, Bird G, Dillon E, Axford I. Prostaglandin analogues in cosmetics: literature review, market survey, analytical method development and testing. 2024.
6. Rahman MS, Yoshida N, Hanafusa M, Matsuo A, Zhu S, Stub Y, et al. Screening and quantification of undeclared PGF2α analogs in eyelash-enhancing cosmetic serums using LC-MS/MS. J Pharm Biomed Anal. 2022;219:114940. doi:10.1016/j.jpba.2022.114940
7. European Commission. Prostaglandins and prostaglandin-analogues used in cosmetic products [Internet]. Brussels: European Commission; 2022 [cited 2026 Sep 28]. Available from: https://health.ec.europa.eu/publications/prostaglandins-and-prostaglandin-analogues-used-cosmetic-products_en
8. Scientific Committee on Consumer Safety. Opinion on prostaglandin analogues: methylamido-dihydro-noralfaprostal (MDN), isopropyl cloprostenate (IPCP), dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE) [Internet]. Brussels: European Commission; 2026 [cited 2026 Sep 28]. Available from: https://health.ec.europa.eu/publications/sccs-prostaglandin-analogues-methylamido-dihydro-noralfaprostal-mdn-isopropyl-cloprostenate-ipcp_en
9. Toklu HZ, Antigua A, Lewis V, Reynolds M, Jones J. Cosmetovigilance: a review of the current literature. J Family Med Prim Care. 2019;8(5):1540–5. doi:10.4103/jfmpc.jfmpc_447_18
10. Vigan M, Castelain F. Cosmetovigilance: definition, regulation and use “in practice”. Eur J Dermatol. 2014;24(6):643–9. doi:10.1684/ejd.2014.2493
11. Renner G, Audebert F, Burfeindt J, Calvet B, Caratas-Perifan M, Leal ME, et al. Cosmetics Europe guidelines on the management of undesirable effects and reporting of serious undesirable effects from cosmetics in the European Union. Cosmetics. 2017;4(1):1. doi:10.3390/cosmetics4010001
12. Benitez B, Anter AM, Arcuri J, Bhattacharya SK. Currently available prostanoids for the treatment of glaucoma and ocular hypertension: a review. Curr Opin Pharmacol. 2023;74:102424. doi:10.1016/j.coph.2023.102424
13. Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13:1015338. doi:10.3389/fphar.2022.1015338
14. Nakakura S, Yamamoto M, Terao E, Nagatomi N, Matsuo N, Fujisawa Y, et al. Prostaglandin-associated periorbitopathy in latanoprost users. Clin Ophthalmol. 2014;8:51–7. doi:10.2147/OPTH.S75651
15. Sullivan DA, da Costa AX, Del Duca E, Doll T, Grupcheva CN, Lazreg S, et al. TFOS Lifestyle: impact of cosmetics on the ocular surface. Ocul Surf. 2023;29:77–130. doi:10.1016/j.jtos.2023.04.005
16. Mathew DJ, Sivak JM. Lipid mediators in glaucoma: unraveling their diverse roles and untapped therapeutic potential. Prostaglandins Other Lipid Mediat. 2024;171:106815. doi:10.1016/j.prostaglandins.2024.106815
17. Malik K, Nicolas S, Dua A. Prostaglandins. In: Wexler P, editor. Encyclopedia of Toxicology. 4th ed. Amsterdam: Elsevier; 2025. p. 993–6. doi:10.1016/B978-0-12-386454-3.00916-7
18. Alm A, Nilsson SFE. Uveoscleral outflow: a review. Exp Eye Res. 2009;88(4):760–8. doi:10.1016/j.exer.2008.12.012
19. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47 Suppl 1:S53–64. doi:10.1016/S0039-6257(02)00306-5
20. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res. 1998;67(2):179–91. doi:10.1006/exer.1998.0508
21. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47 Suppl 1:S185–202. doi:10.1016/S0039-6257(02)00307-7
22. Nesher R, Mimouni M, Elnaddaf H, Nemet A, Kidron D. Characterization of prostaglandin F2α receptors in human eyelids. Eur J Ophthalmol. 2015;25(2):81–4. doi:10.5301/ejo.5000519
23. Bernard BA, Michelet JF, Colombe L. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 2008;17(1):63–72. doi:10.1111/j.1600-0625.2007.00639.x
24. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–58. doi:10.2147/OPTH.S6480
25. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90. doi:10.1016/j.ophtha.2014.05.013
26. Subbulakshmi S, Kavitha S, Venkatesh R. Prostaglandin analogs in ophthalmology. Indian J Ophthalmol. 2023;71(5):1768–74. doi:10.4103/IJO.IJO_2706_22
27. European Glaucoma Society. European Glaucoma Society terminology and guidelines for glaucoma, 5th edition. Br J Ophthalmol. 2021;105 Suppl 1:1–169. doi:10.1136/bjophthalmol-2021-egsguidelines
28. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53 Suppl 1:S107–20. doi:10.1016/j.survophthal.2008.08.010
29. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53 Suppl 1:S93–105. doi:10.1016/j.survophthal.2008.08.004
30. Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast Surg. 2011;35(1):116–21. doi:10.1007/s00266-010-9561-3
31. Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014;8:903–13. doi:10.2147/OPTH.S44708
32. Sánchez González JM, Gandullo-Asuar M, Ballesteros Sánchez A, Sánchez-González MC, Hernández-Lucena J, Capote-Puente R, et al. Effect of a prostaglandin analog-based eyelash serum on tear film stability and the ocular surface. Eye Contact Lens. 2026;52(9):368–74. doi:10.1097/ICL.0000000000001300
33. Abalo-Lojo JM, Ferreiro PV, Asorey MK, Colmenero AE, Gonzalez F. Improvement of prostaglandin-associated periorbitopathy after discontinuing treatment. Turk J Ophthalmol. 2023;53(1):8–12. doi:10.4274/TJO.GALENOS.2022.24365
34. Monge-Carmona R, Caro-Magdaleno M, Sánchez-González MC. Association between the use of prostaglandin analogues and ocular surface disease: a systematic review. Eye (Lond). 2025;39(1):28–39. doi:10.1038/s41433-024-03372-y
35. Lindén C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999;14(5):387–98. doi:10.2165/00002512-199914050-00006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Agnieszka Strakowska, Mateusz Anczakowski, Hanna Komedera, Nikodem Oślizło, Roksana Sroga, Julia Śmierzyńska, Aleksandra Filip, Aleksandra Witkowska, Karolina Suchanek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 60
Number of citations: 0
